Clinical Trial Search

Phase 2 N=47 Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

Healthy Volunteers · hATTR Amyloidosis

Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 3; 1; 3; 7 Participants

Ionis Pharmaceuticals, Inc. Results Dec 2022 0.0% serious AE View details

Phase 2 N=182 A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Advanced Cancer

Primary: Objective Response Rate (ORR) Per Investigator — 20; 30; 17.4; 3.1 Percent of participants

Bristol-Myers Squibb Results Dec 2022 54.7% serious AE View details

Phase 3 N=783 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 27.7; 36.0 Percentage of participants — p=0.0311

Bristol-Myers Squibb Results Dec 2022 43.3% serious AE View details

Phase 2 N=509 A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

Respiratory Syncytial Virus Infections

Primary: Percentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study] — 5.9; 5; 5.8; 5.9 Percentage of participants

GlaxoSmithKline Results Dec 2022 0.4% serious AE View details

Phase 3 N=2,629 Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

HIV Infections

Primary: Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. — 71; 97 Participants

International Partnership for Microbicides, Inc. Results Dec 2022 9.4% serious AE View details

Phase 2 N=183 A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Primary: Number of Participants Achieving a Combined Clinical Response Using the Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24 — 37; 31 Participants…

Cephalon, Inc. Results Dec 2022 12.0% serious AE View details

N/A N=118 Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study

Pregnancy

Primary: Total Visit Number — 7.9; 10.2 visits — p=<0.001

Andrew Meltzer Results Dec 2022 0.0% serious AE View details

N/A N=2,102 Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk

Human Immunodeficiency Virus

Primary: HIV Incidence Per 100 Person Years — 1.18; .98 cases per 100 person years

University of Pennsylvania Results Dec 2022 0.0% serious AE View details

Phase 2 N=20 Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Primary: Objective Response Rate (ORR) Based on Independent Reviewer Assessment — 76.5; 100.0 percentage of participants

Eisai Co., Ltd. Results Dec 2022 45.0% serious AE View details

N/A N=48 Total30 Sphere Contact Lenses

Contact Lens Complication · Dry Eye

Primary: Visual Analog Scale (VAS) Ocular Comfort — 36.66; 38.06; 33.68; 39.36 units on a scale — p=0.07

University of Alabama at Birmingham Results Dec 2022 0.0% serious AE View details

Phase 4 N=46 Esthetic Outcomes Following Immediate Implant Combine With Soft Tissue Augmentation

Dental Implant · Immediate Dental Implant · Soft Tissue Augmentation

Primary: Change in Ridge Dimension — -1.65; -1.87; -1.44; -1.37 millimeters (mm)

The University of Texas Health Science Center… Results Dec 2022 0.0% serious AE View details

N/A N=82 Building a Bridge (BAB) Between Clinical and Community Care

Caregiver Burden

Primary: Modified Zarit Burden Interview — 19.429; 17.950; 32.207; 27.160 Burden score — p=0.206

Sato Ashida Results Dec 2022 0.0% serious AE View details

Phase 4 N=199 Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen

Pelvic Organ Prolapse · Urogenital Prolapse · Vaginal Vault Prolapse

Primary: Surgical "Failure" Defined by (i) Anatomic Assessment of Prolapse, (ii) Presence of Bulge Symptoms, and/or (Iii) Retreatment of Prolapse — 18; 8 Participants

University of Texas Southwestern Medical Center Results Dec 2022 10.5% serious AE View details

Phase 3 N=113 A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Motor OFF Episodes Associated With Parkinson's Disease

Primary: Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each…

Sumitomo Pharma America, Inc. Results Dec 2022 0.9% serious AE View details

Phase 3 N=289 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

Psoriasis

Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003

Amgen Results Dec 2022 1.4% serious AE View details